These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 8374609

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Nitric oxide synthase I immunoreactivity in the macula densa of the kidney is angiotensin II dependent.
    Murakami K, Tsuchiya K, Naruse M, Naruse K, Demura H, Arai J, Nihei H.
    Kidney Int Suppl; 1997 Dec; 63():S208-10. PubMed ID: 9407461
    [Abstract] [Full Text] [Related]

  • 23. Cyclooxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension.
    Wang JL, Cheng HF, Harris RC.
    Hypertension; 1999 Jul; 34(1):96-101. PubMed ID: 10406830
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Acute hemodynamic effects of ciprokiren, a novel renin inhibitor, in sodium-depleted dogs.
    Clozel JP, Véniant M, Sprecher U, Fischli W.
    J Cardiovasc Pharmacol; 1995 Oct; 26(4):674-7. PubMed ID: 8569232
    [Abstract] [Full Text] [Related]

  • 27. Effects of captopril and enalapril on sodium excretion and blood pressure in sodium-deficient dogs.
    McCaa RE, Gillespie JB.
    Fed Proc; 1984 Apr; 43(5):1336-41. PubMed ID: 6323226
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Cardiovascular effects and hemodynamic mechanism of action of the novel, nonpeptidic renin inhibitor A-74273 in dogs.
    Wessale JL, Calzadilla SV, Boyd SA, Baker WR, Stein HH, Kovar PJ, Barlow J, Klinghofer V, Mantei R, Kleinert HD.
    J Cardiovasc Pharmacol; 1993 Oct; 22(4):644-52. PubMed ID: 7505369
    [Abstract] [Full Text] [Related]

  • 31. Pharmacological properties of YM-21095, a potent and highly specific renin inhibitor.
    Shibasaki M, Asano M, Fukunaga Y, Usui T, Ichihara M, Murakami Y, Nakano K, Fujikura T.
    Am J Hypertens; 1991 Dec; 4(12 Pt 1):932-8. PubMed ID: 1815649
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. An orally active renin inhibitor: cyclohexylnorstatine-containing dipeptide (KRI-1314).
    Miyazaki M, Etoh Y, Iizuka K, Toda N.
    J Hypertens Suppl; 1989 Apr; 7(2):S25-7. PubMed ID: 2666609
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Neurohormonal and blood pressure responses to low-dose infusion of an orally active renin inhibitor, Ro 42-5892, in salt-replete men.
    Doig JK, MacFadyen RJ, Meredith PA, Fischli W, Reid JL.
    J Cardiovasc Pharmacol; 1992 Dec; 20(6):875-80. PubMed ID: 1282588
    [Abstract] [Full Text] [Related]

  • 38. Effects of a novel renin inhibitor in patients with essential hypertension.
    Bursztyn M, Gavras I, Tifft CP, Luther R, Boger R, Gavras H.
    J Cardiovasc Pharmacol; 1990 Mar; 15(3):493-500. PubMed ID: 1691375
    [Abstract] [Full Text] [Related]

  • 39. Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects.
    Müller P, Cohen T, de Gasparo M, Sioufi A, Racine-Poon A, Howald H.
    Eur J Clin Pharmacol; 1994 Mar; 47(3):231-45. PubMed ID: 7867676
    [Abstract] [Full Text] [Related]

  • 40. Clinical pharmacology of enalkiren, a novel, dipeptide renin inhibitor.
    Glassman HN, Kleinert HD, Boger RS, Moyse DM, Griffiths AN, Luther RR.
    J Cardiovasc Pharmacol; 1990 Mar; 16 Suppl 4():S76-81. PubMed ID: 1705633
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.